Panu Miettinen appointed chief financial officer of Biotie
February 16, 2012Business Services, Research and Development, Sales and Marketing Biotie, Panu Miettinen
Panu Miettinen, 43, has been appointed chief financial officer of Biotie Therapies. He will become a member of the Group’s …
EMA appoints new head of information and communications technology
February 16, 2012Business Services, Medical Communications, Sales and Marketing EMA, Luc Verhelst
Luc Verhelst has been appointed as the new head of the European Medicines Agency’s information and communications technology unit. Verhelst …
MRN launches online training portal
February 16, 2012Research and Development
16 February 2012 – Medical Research Network (MRN), the unique Clinical Trial Support Organisation (CTSO) offering home trial support, site …
NICE frowns on Botox for headache prevention
February 16, 2012Sales and Marketing Allergan, Botox, EMA, NHS, NICE
NICE is not recommending Allergan’s Botox for headache prevention, and has asked the firm for more information on the drug. …
Amgen appoints Michael Severino as senior vice president, Global Development and Corporate chief medical officer
February 16, 2012Business Services, Research and Development, Sales and Marketing
Michael Severino has been named senior vice president, Global Development and Corporate chief medical officer at Amgen.Severino, 46, formerly vice president, …
Teva launches generic Aricept in the UK
February 16, 2012Manufacturing and Production, Sales and Marketing Alzheimer's, Aricept, NHS, Pfizer, Teva
Teva has launched its generic version of Alzheimer’s drug Aricept, as the drug loses its patent protection in the UK. …
Emerging markets no haven from HTA, says NICE
February 15, 2012Andrew Witty, GSK, NICE, NICE International
The head of NICE says pharma will face health technology assessment barriers in every country – including fast-growing developing markets. …
Most patients happy with hospital care
February 15, 2012Sales and Marketing NHS, hospital, patient survey
A new survey has found that the vast majority of NHS patients receiving outpatient hospital care are happy with the …
FDA accepts Pfizer rare disease drug for review
February 15, 2012Sales and Marketing EMA, FDA, FoldRx, Pfizer, tafamidis meglumine
The FDA has accepted for review Pfizer’s new drug to treat a rare neurodegenerative disease. Pfizer is seeking a licence …
Diabetes – the battle for control
February 15, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Novo Nordisk, Sanofi, Victoza, degludec, diabetes
This year marks the 90th anniversary of the first ever successful use of insulin to treat patients with type I …
Strategic North appoints Paula Lashley as consultant
February 15, 2012Business Services, Medical Communications, Sales and Marketing
Healthcare strategic marketing consultancy Strategic North, who recently reached the final of the Manchester Evening News Business of the Year …
New categories for IPA Best of Health Awards
February 15, 2012Medical Communications Best of Health, IPA
This year’s IPA Best of Health Awards are now open for entries from healthcare advertising agencies worldwide. The annual awards …
Pharma critical of Obama budget
February 15, 2012Research and Development, Sales and Marketing IPAB, Independent Payment Advisory Board, Medicare, Obama, PhRMA, US, healthcare reform
President Obama has unveiled a new budget which aims to cut the US deficit by $4 trillion over the next …
Watchdog frowns on Botox tweet
February 15, 2012Medical Communications Allergan, Chugai, PMCPA, Twitter
Allergan have been found in breach of the UK Code of Practice after an employee used Twitter to communicate about …
Market access: Communicating the story effectively
February 15, 2012Medical Communications
By Andy Buckland – Principal Medical Writer at Abacus International Successful market access relies on a multitude of activities throughout …
Biogen to pay $563 million for Stromedix
February 15, 2012Research and Development, Sales and Marketing Bioden Idec, R&D, STX-100, Stromedix
Biogen Idec will acquire the specialist immunology firm Stromedix for around $500 million. Biogen currently focuses on the development of …
Ablynx appoints Dr Andreas Menrad as its new chief scientific officer
February 15, 2012Business Services, Research and Development, Sales and Marketing Abllynx, Menrad, nanobody
Dr Andreas Menrad has joined the Belgium-based firm Ablynx as its new chief scientific officer. Dr Menrad has over 20 …
New PV Legislation Implementation Plan by the European Medicines Agency
February 14, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing wainwright associates; Pharmacovigilance legislation
The European Medicines Agency has released an implementation plan for the pharmacovigilance legislation, which sets out milestone dates for different …
Virgo bolsters specialist value and access service
February 14, 2012Medical Communications Jo Jones, NHS, Virgo, Virgo Health Communications
Virgo Health Communications has expanded its UK value and access expertise with the appointment of Tristan Mulholland.Tristan joins as Account …
Merck’s eye drug Zioptan gains FDA approval
February 14, 2012Sales and Marketing Merck, Pfizer, Xalatan, Zioptan
The FDA has approved Merck’s eye solution Zioptan to treat a common eye condition. Zioptan (tafluprost ophthalmic solution) can now …
Latest content
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
